• Explore /
  • Poster
  • / Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Abstract Poster

Authors

Ahmed Kaseb

Ahmed Omar Kaseb

GI Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX

Ahmed Omar Kaseb , Hop Sanderson Tran Cao , Yehia I. Mohamed , Aliya Qayyum , Luis M. Vence , Jorge M. Blando , Shalini Singh , Sunyoung S. Lee , Kanwal Pratap Singh Raghav , Lina Altameemi , Asif Rashid , Jean-Nicolas Vauthey , Kristen Carter , Ching-Wei David Tzeng , Yun Shin Chun , James C. Yao , Robert A. Wolff , James Patrick Allison , Padmanee Sharma

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03222076.

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4599)

DOI

10.1200/JCO.2020.38.15_suppl.4599

Abstract #

4599

Poster Bd #

207

Abstract Disclosures

Similar Posters

First Author: Ahmed Omar Kaseb

First Author: Ahmed Omar Kaseb

First Author: Yara L. Verschoor

First Author: Milton Jose De Barros E Silva